Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Alnylam Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
ALNY
Nasdaq
2834
https://www.alnylam.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Alnylam Pharmaceuticals, Inc.
Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
- Apr 18th, 2024 12:00 pm
Why Alnylam Pharmaceuticals (ALNY) Stock Might be a Great Pick
- Apr 8th, 2024 12:44 pm
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
- Apr 7th, 2024 12:00 pm
Those who invested in Alnylam Pharmaceuticals (NASDAQ:ALNY) five years ago are up 63%
- Mar 29th, 2024 11:19 am
Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
- Mar 20th, 2024 12:00 pm
30 Biggest Biotechnology Companies in the World
- Mar 17th, 2024 12:50 pm
Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
- Mar 13th, 2024 11:30 am
Alnylam (ALNY), Roche's Blood Pressure Drug Meets Study Goal
- Mar 6th, 2024 4:26 pm
Roche, Alnylam say blood pressure drug succeeds in mid-stage trial
- Mar 5th, 2024 1:27 pm
Alnylam, Roche blood pressure drug scores in second mid-stage trial
- Mar 5th, 2024 12:52 pm
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
- Mar 5th, 2024 12:30 pm
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
- Feb 27th, 2024 1:30 pm
Alnylam Pharmaceuticals Full Year 2023 Earnings: In Line With Expectations
- Feb 17th, 2024 1:12 pm
Alnylam (ALNY) Q4 Loss Narrower Than Expected, Stock Dips 10%
- Feb 16th, 2024 5:08 pm
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2023 Earnings Call Transcript
- Feb 16th, 2024 2:46 pm
Q4 2023 Alnylam Pharmaceuticals Inc Earnings Call
- Feb 16th, 2024 6:55 am
Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight
- Feb 16th, 2024 5:02 am
Why Alnylam Pharmaceuticals Stock Is Sinking Today
- Feb 15th, 2024 5:39 pm
Alnylam (ALNY) Reports Q4 Earnings: What Key Metrics Have to Say
- Feb 15th, 2024 3:30 pm
Alnylam Pharmaceuticals Inc (ALNY) Reports Strong Growth in 2023, Aiming for Continued Success ...
- Feb 15th, 2024 1:37 pm
Scroll